Lipid metabolic alterations in obesity;Alteraciones del metabolismo lipídico en la obesidad

Revista Espanola de Obesidad

Volumn 4, Issue 5, 2006, Pages 261-274

  Aguilera García, Concepción María ^a   Gil Campos, Mercedes ^b   Cañete Estrada, Ramón ^b   Gil Hernández, Ángel ^a,b  

^a UNIVERSITY OF GRANADA   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; LEPTIN; LIPID;

CARDIOVASCULAR RISK; FATTY ACID OXIDATION; GLUCONEOGENESIS; HUMAN; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPID METABOLISM; METABOLIC SYNDROME X; OBESITY; REVIEW;

EID: 33751306476     PISSN: 16966112     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Gil Hernández A. Obesidad y genes. Vox Paediatrica 2002; 10: 4045.
2. Astrup A, Buemann B, Christensen NJ, Toubro S. Failure to increase lipid oxidation in response to increasing dietary fat content in formerly obese women. Am J Physiol 1994; 266: E592-599.
3. Filozof CM, Murua C, Sánchez MP, Brailovsky C, Perman M, Gonzalez CD, et al. Low plasma leptin concentration and low rates of fat oxidation in weight-stable post-obese subjects. Obes Res 2000; 8: 205-10.
4. Sampath H, Ntambi JM. Stearoyl-coenzyme A desaturase 1, sterol regulatory element binding protein-1c and peroxisome proliferator-activated receptor-alpha: independent and interactive roles in the regulation of lipid metabolism. Curr Opin Clin Nutr Metab Care. 2006; 9: 84-8.
5. Rankinen T, Zuberi A, Chagnon YC, Weisnagel SJ, Argyropoulos G, Walts B, et al. The human obesity gene map: the 2005 update. Obesity 2006; 14: 529-644.
6. Reaven GM. Pathophysiolgy of insulin resistance in human disease. Physiol Rev 1995; 75: 473-486.
7. Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr 2005; 25: 391-406.
8. Alberti K, Zimmet P & Consultation W. Definition diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabetic Medicine 1998; 15: 539-553.
9. Weiss R, Dufour S, Taksali S, Tamborlane W, Petersen K, Bonadonna R, Boselli L, Barbetta G, Allen K, Rife F, Savoye M, Dziura J, Sherwin R, Shulman G, Caprio S. Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Lancet 2003; 362: 951-957.
10. Haslam DW, James WPT. Obesity. Lancet 2005; 366: 1197-209.
11. Reinehr T, Holl RW, Roth CL, Wiesel T, Stachow R, Wabitsch M, Andler W, DPV-Wiss Study Group. Insulin resistance in children and adolescents with type 1 diabetes mellitus: relation to obesity. Pediatr Diabetes 2005; 6: 3-4.
12. Goldstein BJ. Insulin resistance as the core defect in type 2 diabetes Mellitus. Am J Cardiol 2002; 90 (Suppl): 3G-10G.
13. Kopelman PG. Obesity as a medical problem. Nature 2000; 404: 635-643.
14. Valle M, Gascón F, Martos R, Bermudo F, De Torres G, Cañete R. Apolipoproteins in the obese child: Correlation with antropometric measures and insulin levels. Clin Chem Lab Med 1999; 37: 276.
15. Valle M, Gascón F, Martos R, Ruz FJ, Bermudo F, Ríos R, Cañete R. Infantile Obesity: A situation of atherothrombotic risk? Metabolism 2000; 49: 672-675.
16. Valle M, Gascón F, Martos R, Ruiz F, Rios R, Cañete R. Apo A-I decrease and tryglicerides increase serum levels in hiperinsulinemic children. Clin Chem Lab Med 2001; 39: 247.
17. Brunzell JD, Hokanson JE. Low-density and high-density lipoprotein subspecies and risk for premature coronary artery disease. Am J Med 1999; 107: 16S-18S.
18. Zammit VA, Waterman IJ, Topping D, McKay G. Insulin stimulation of hepatic triacylglycerol secretion and the etiology of insulin resistance. J Nutr 2001; 131: 2074-77.
19. Gil-Campos M, Canete R, Gil A. Hormones regulating lipid metabolism and plasma lipids in childhood obesity. Int J Obes Relat Metab Disord 2004; 3: S75-80.
20. Syvanne M, Taskinen MR. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 1997; 350: SI20-3.
21. Caprio S, Bronson M, Sherwin RS, Rife F, Tamborlane WV. Coexistence of severe insulin resistance and hyperinsulinaemia in pre-adolescent obese children. Diabetologia 1996; 39: 1489-97.
22. Valle M, Gascón F, Martos R, Ruz FJ, Bermudo F, Morales R, Cañete R. Metabolic cardiovascular syndrome in obese prepubertal children: the role of high fasting insulin levels. Metabolism 2002; 51: 423-428.
23. Arslanian S, Suprasongsin C. Insulin sensitivity, lipids, and body composition in childhood: is "syndrome X" present? J Clin Endocrinol Metab 1996; 81: 1058-62.
24. Steinbeck KS, Bermingham MA, Mahajan D, Baur LA. Low-density lipoprotein subclasses in children under 10 years of age. J Paediatr Child Health 2001; 37: 550-553.
25. Moreno MJ, Martínez JA. El tejido adiposo: órgano de almacenamiento y órgano secretor. Anales Sis San Navarra 2002; 25: 29-39.
26. He Q, Ding ZY, Yee-Tak D, Karlberg J. Blood pressure is associated with body mass index in both mormal and obese children. Hypertension 2000; 36: 165-170.
27. Jensen MD. Health consequences of fat distribution. Horm Res 1997; 48: 88-92.
28. Sprangers F, Romijn JA, Endert E, Ackermans MT, Sauerwein HP. The role of free fatty acids (FFA) in the regulation of intrahepatic fluxes of glucose and glycogen metabolism during short-term starvation in healthy volunteers. Clin Nutr 2001; 20: 177-179.
29. Bergman RN, Ader M. Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 2000; 11: 351-6.
30. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocrine Reviews 2000; 21: 697-738.
31. Chen X, Iqbal N, Boden G: The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjets. J Clin Invest 1999; 103: 365-72
32. Grill V, Qvigstad E: Fatty acids and insulin secretion. Br J Nutr 2000; 83: 79-84.
33. Bakker SJ, Gans RO, ter Maaten JC, Teerlink T, Westerhoff HV, Heine RJ. The potential role of adenosine in the pathophysiology of the insulin resistance syndrome. Atherosclerosis 2001; 155: 283-290.
34. Borrajo E. Aspectos actuales de la obesidad. An Esp Pediatr 2002; 56 (supl 4): 1-11.
35. Ruderman NB, Saha AK, Kraegen EW. Minireview: malonyl CoA, AMP-activated protein kinase, and adiposity. Endocrinology 2003; 144: 5166-71.
36. Ruderman NB, Saha AK, Vavvas D, Heydrick SJ, Kurowski TG. Lipid abnormalities in muscle of insulin-resistant rodents. The malonyl CoA hypothesis. Ann N Y Acad Sci 1997; 827: 221-30.
37. Kohen-Avramoglu R, Theriault A, Adeli K. Emergence of the metabolic syndrome in childhood: an epidemiological overview and mechanistic link to dyslipidemia. Clin Biochem 2003; 36: 413-20.
38. Hosokawa H, Corkey BE, Leahy JL. Beta-cell hypersensitivity to glucose following 24-h exposure of rat islets to fatty acids. Diabetologia 1997; 40: 392-97.
39. Shimabukuro M, Zhou YT, Levi M, Unger RH. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A 1998; 95: 2498-502.
40. Kahn S, Prigeon R, Schwartz R, Fujimoto W, Knoop R, Brunzell J, Porte D. Obesity, body fat distribution, insulin sensitivity and islet β-cell function as explanations for metabolic diversity. J Nutr 2001; 131: 354-360.
41. Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-α. Cytokine & Growth Factor Reviews 2003; 14: 447-55.
42. Gil-Campos M, Canete R, Gil A. Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr 2004; 23: 963-74.
43. Rossner S, Walldius G, Bjorvell H. Fatty acid composition in serum lipids and adipose tissue in severe obesity before and after six weeks of weight loss. Int J Obes 1989; 13: 603-12.
44. Phinney SD, Tang AB, Thurmond DC, Nakamura MT, Stern JS. Abnormal polyunsaturated lipid metabolism in the obese Zucker rat, with partial metabolic correction by gamma-linolenic acid administration. Metabolism 1993; 42: 1127-40.
45. Phinney SD, Fisler JS, Tang AB, Warden C. Liver fatty acid composition correlates with body fat and gender in a multigenic mouse model of obesity. Am J Clin Nutr 1994; 60: 61-7.
46. Kunesova M, Hainer V, Tvrzicka E, Phinney SD, Stich V, Parizkova J, et al. Serum and adipose tissue fatty acid composition in female obese identical twins. Lipids 2002; 37: 27-32.
47. Vessby B. Dietary fat, fatty acid composition in plasma and the metabolic syndrome. Curr Opin Lipidol 2003; 14: 15-9.
48. Tremblay AJ, Despres JP, Piche ME, Nadeau A, Bergeron J, Almeras N, et al. Associations between the fatty acid content of triglyceride, visceral adipose tissue accumulation, and components of the insulin resistance syndrome. Metabolism 2004; 53: 310-7.
49. Agostoni C, Riva E, Bellu R, Vincenzo SS, Grazia BM, Giovannini M. Relationships between the fatty acid status and insulinemic indexes in obese children. Prostaglandins Leukot Essent Fatty Acids 1994; 51: 317-21.
50. Decsi T, Molnar D, Koletzko B. Long-chain polyunsaturated fatty acids in plasma lipids of obese children. Lipids 1996; 31: 305-11.
51. Decsi T, Csabi G, Torok, K, Erhardt E, Minda H, Burus I, Molnar S, Molnar D. Polyunsaturated fatty acids in plasma lipids of obese children with and without metabolic cardiovascular syndrome. Lipids 2000; 35: 1179-84.
52. Klein-Platat K, Drai J, Oujaa M, Schlienger JL, Simon C. Plasma fatty acid composition is associated with the metabolic syndrome and low-grade inflammation in overweight adolescents. Am J Clin Nutr 2005; 82: 1178-84.
53. Baur L, O'Connor J, Pan DA, Kriketos AD, Storlien LH. The fatty acid composition of skeletal muscle membrane phospholipid: its relationship with the type of feeding and plasma glucose levels in young children. Metabolism 1998; 47: 106-12.
54. Phinney SD. Fatty acids, inflammation and metabolic syndrome. Am J Clin Nutr 2005; 82: 1151-52.
55. Larqué E, Gil-Campos M, Ramirez-Tortosa MC, Linde J, Cañete R, Gil A. Postprandial response of trans fatty acids in prepubertal obese children. Int J Obes 2006; 30: 1488-93.
56. Garaulet M, Pérez-Llamas F, Pérez-Ayala M, Martínez P, Sánchez de Medina F, Tébar FJ, Zamora S. Site-specific differences in the fatty acid composition of abdominal adipose tissue in ano bese population from a Mediterranean area: relation with dietary fatty acids, plasma lipid profile, serum insulin, and central obesity. Am J Clin Nutr 2001; 74: 585-91.
57. Warensjo E, Riserus U, Vessby B. Fatty acid composition of serum lipids predicts the development of the metabolic syndrome in men. Diabetologia 2005; 48: 1999-05.
58. Ravussin E, Smith SR. Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. Ann NY Acad Sci 2002; 967: 363-78.
59. Unger RH, Orci L. Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J 2001; 15: 312-21.
60. Baile CA, Della-Fera MA, Martín RJ. Regulation of metabolism and body fat mass by leptin. Annu Rev Nutr 2000; 20: 105-27.
61. Friedman JM. Obesity in the new millennium. Nature 2000; 404: 632-634.
62. Friedman JM: Leptin, leptin receptors, and the control of body weight. Nutr Rev 1998; 56: 3846.
63. Neel JV, Weder AB, Julius S. Type II diabetes, essential hypertension, and obesity as "syndromes of impaired genetic homeostasis": the "thrifty genotype" hypothesis enters the 21st century. Perspect Biol Med 1998; 42: 44-74.
64. Lee Y, Wang MY, Kakuma T, Wang ZW, Babcock E, McCorkle K, et al. Liporegulation in diet-induced obesity. The antisteatotic role of hyperleptinemia. J Biol Chem 2001; 276: 5629-35.
65. Steinberg GR, Parolin ML, Heigenhauser GJ, Dyck DJ. Leptin increases FA oxidation in lean but not obese human skeletal muscle: evidence of peripheral leptin resistance. Am J Physiol Endocrinol Metab 2002; 283: E187-92.
66. Unger RH. The physiology of cellular liporegulation. Annu Rev Physiol 2003; 65: 33347.
67. Unger RH. Hyperleptinemia: protecting the heart from lipid overload. Hypertension 2005; 45: 1031-4.
68. Oral EA, Ruiz E, Andewelt A, Sebring N, Wagner AJ, Depaoli AM, Gorden P. Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy. J Clin Endocrinol Metab 2002; 87: 3110-7.
69. Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Gorden P. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes 2005; 54: 1994-2002.
70. Cañete R, Gil M, Poyato JL. Obesidad en el niño: nuevos conceptos de etiopatogenia y tratamiento. Pediatr Integral 2003; 7: 480-90.
71. Groop L. Pathogenesis of type 2 diabetes: the relative contribution of insulin resistance and impaired insulin secretion. Int J Clin Pract Suppl 2000; 113: 3-13.
72. Minokoshi Y, Kahn BB. Role of AMP-activated protein kinase in leptin-induced fatty acid oxidation in muscle. Biochem Soc Trans 2003; 31: 196-201.
73. Andersson U, Filipsson K, Abbott CR, Woods A, Smith K, Bloom SR, et al. AMP-activated protein kinase plays a role in the control of food intake. J Biol Chem 2004; 279: 12005-8.
74. Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, Xue B, Mu J, et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 2004; 428: 569-74.
75. Beltowski J. Adiponectin and resistin-new hormones of white adipose tissue. Med Sci Monit 2003; 9: RA55-61.
76. Stefan N, Stumvoll M. Adiponectin-its role in metabolism and beyond. Horm Metab Res 2002; 34: 469-74.
77. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
78. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003; 148: 293-300.
79. Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002; 51: 1884-8.
80. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-95
81. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002; 8: 731-7.
82. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-9.
83. Erratum in: Nature 2004; 431: 1123.
84. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 2001; 98: 2005-10.
85. Lam TK, Schwartz GJ, Rossetti L. Hypothalamic sensing of fatty acids. Nat Neurosci 2005; 8: 579-84.
86. Woods SC, Stein LJ, McKay LD, Porte D Jr. Supression of food intake by intravenous nutrients and insulin in the baboon. Am J Phisiol 1984; 247: 393-401.
87. Obici S, Feng Z, Karkanias G, Baskin DG, Rossetti L. Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. Nat Neurosci 2002; 5: 566-72.
88. Morgan K, Obici S, Rossetti L. Hypothalamic responses to long-chain fatty acids are nutritionally regulated. J Biol Chem 2004; 279: 31139-48.
89. Obici S, Feng Z, Morgan K, Stein D, Karkanias G, Rossetti L. Central administration of oleic acid inhibits glucose production and food intake. Diabetes 2002; 51: 271-5.
90. Lam TK, Pocai A, Gutierrez-Juarez R, Obici S, Bryan J, Aguilar-Bryan L, Schwartz GJ, Rossetti L. Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis. Nat Med 2005; 11: 320-7.
91. Obici S, Feng Z, Arduini A, Conti R, Rossetti L. Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production. Nat Med 2003; 9: 756-61.
92. Kim EK, Miller I, Landree LE, Borisy-Rudin FF, Brown P, Tihan T. Townsend CA, Witters LA, Moran TH, Kuhajda FP, Ronnett GV. Expression of FAS within hypothalamic neurons: a model for decreased food intake after C75 treatment. Am J Physiol Endocrinol Metab 2002; 283: E867-79.
93. Clegg DJ, Wortman MD, Benoit SC, McOsker CC, Seeley RJ. Comparison of central and peripheral administration of C75 on food intake, body weight, and conditioned taste aversion. Diabetes 2002; 51: 3196-201.
94. Makimura H, Mizuno TM, Yang XJ, Silverstein J, Beasley J, Mobbs CV. Cerulenin mimics effects of leptin on metabolic rate, food intake, and body weight independent of the melanocortin system, but unlike leptin, cerulenin fails to block neuroendocrine effects of fasting. Diabetes 2001; 50: 733-9.
95. Loftus TM, Jaworsky DE, Frehywot GL, Townsend CA, Ronnett GV, Lane MD, Kuhajda FP. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 2000; 288: 2379-81.